Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

111.09 +1.64 (+1.50%)
Streaming Delayed Price Updated: 11:30 AM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
News headline image
Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock ↗
Discover Merck (MRK), a top dividend stock with a 3.76% yield, strong growth history, and excellent financial health for sustainable income. 
Via Chartmill
News headline image
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
From Merck & Co., Inc.
Via Business Wire
News headline image
Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health' ↗
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public... 
Via Benzinga
Topics Government
CSX, Intel, Palantir, Nvidia, Merck: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗
Via Stocktwits
News headline image
Merck to Participate in the 2025 Wells Fargo Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
1 Safe-and-Steady Stock Worth Your Attention and 2 We Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Topics Bonds
News headline image
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst ↗
Summit and Akeso report ivonescimab's survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger. 
Via Benzinga
News headline image
EU Rushes To Scrap Tariffs On US Goods To Unlock Lower American Auto Duties: These Exporters Stand To Gain Big ↗
EU set to scrap tariffs on U.S. goods in a key auto trade deal. See which American industrial and energy stocks are poised for a boost. 
Via Benzinga
Topics World Trade
News headline image
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
From Merck & Co., Inc.
Via Business Wire
News headline image
Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside ↗
Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy. 
Via Stocktwits
News headline image
As the Market Rotates, This Healthcare ETF Is Leading the Way ↗
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure. 
Via MarketBeat
Topics ETFs
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts ↗
Powell’s dovish Jackson Hole remarks signal that the Fed could cut rates as early as September, with markets now pricing an 80% chance of a 25 bps cut. 
Via MarketBeat
Topics ETFs Economy
News headline image
HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform ↗
HCW Biologics shares jump after unveiling TRBC-based fusion therapy that enhances immune response and shows strong preclinical results in solid tumors. 
Via Benzinga
News headline image
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025
From Merck & Co., Inc.
Via Business Wire
News headline image
What's going on in today's session: S&P500 movers ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday. 
Via Chartmill
News headline image
Slocum Gordon Exits Stake in Kimberly-Clark Worth Nearly $3 Million ↗
Via The Motley Fool
News headline image
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds
From Merck & Co., Inc.
Via Business Wire
News headline image
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
2 Value Stocks on Our Watchlist and 1 Facing Challenges
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
2 Top Dividend Stocks to Buy on the Dip ↗
These blue chip healthcare stocks could still deliver strong long-term returns. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
MERCK & CO. INC. (NYSE:MRK) – A Strong Value Investment with Undervalued Potential ↗
Merck & Co. (MRK) is a strong value stock with low P/E, high earnings, stable finances, and a reliable dividend—ideal for long-term investors. 
Via Chartmill
News headline image
Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck (NYSE:MRK) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Dividend Investor Earning $5,200 A Month Shares His Top 7 Stock Picks – 'Getting Dividend is the Biggest Joy in My Life' ↗
 
Via Benzinga
News headline image
3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever ↗
A good stock is an even better buy when it's on sale. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks ↗
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive. 
Via The Motley Fool
Topics Retirement
News headline image
MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was... 
Via StockStory
News headline image
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy. 
Via Benzinga
News headline image
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.